Int Number	Eudra-CT-No	Design	Study Population Target indication	Participants	Duration
K173	2006-003777-27	A monocenter prospective open-label single rising dose study with a new monoclonal antibody, FIM	healthy volunteers Psoriasis	57	02/07 - 01/09
K238	2007-001609-81	Multicenter, two-part, open-label, dose escalation, FIM, Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibodycytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer	Advanced Pancreatic cancer	6	05/08 - 04/11
K266	2010-022776-31	Open-label, single center phase I trial to investigate the safety, tolerability and pharmacokinetics of Myrcludex B (FIM)	healthy volunteers Hepatitis B	36	07/11 - 10/14
K339	2009-015942-50	Open-label, multicentre, dose-escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 in adult subjects with relapsed/refractory multiple myeloma as monotherapy and in combination with standard therapy (FIM)	Multiple Myeloma	43	08/11 - ongoing
K239	2011-000222-29	First-in-human, monocenter, double-blind, placebo-controlled, phase I dose escalation study to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01	Pancreatic cancer	72	12/11 - 09/14
K394	2010-019191-79	An open-label, Phase I, dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1000394 given in 3 days on/4 days off schedule (FIM)	CLL, NHL and Hodgkin Lymphoma	2	09/12 - 04/13
K372	2011-003820-10	A multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 (FIM)	Multiple Myeloma	38	11/12 - ongoing
K404	2013-001923-38	A double-blind, randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of the plasmacytoid dendritic cell specific humanized monoclonal antibody MB101 (FIM)	Psoriasis	9	12/13 - 01/17
K436	2012-004671-39	A Phase I, multi-center, non-randomized, open-label, dose escalation design study to characterize safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY 1125976 (FIM)	Advanced Tumors	30	12/13 - 01/17
K523	2015-002922-38	A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Preliminary Activity of Oral ACY-241 Alone and in Combination with Pomalidomide and Low-Dose Dexamethasone, (FIM)	Relapsed and Refractory Multiple Myeloma (RRMM)	7	03/16 - 03/17

Int Number	Eudra-CT-No	Design	Study Population Target indication	Participants	Duration
K546	2014-002609-39	An open-label dose-escalation study designed to evaluate the safety and pharmacokinetics of ABBV-838 and determine the recommended Phase 2 dose of ABBV-838	Relapsed and Refractory Multiple Myeloma (RRMM)	6	03/16 - 03/18
K309	2016-002463-33	A phase I study to assess the safety and immunogenicity of the HD-MSP1-Vac1 malaria vaccine in healthy volunteers	Healthy volunteers Malaria vaccination	32	04/17 -
K588	2016-003624-22	Phase I open label, multi-center study to characterize the safety, tolerability and pharmacokinetics of intravenously administered MIK665, a Mcl-1 inhibitor	Relapsed and Refractory Multiple Myeloma (RRMM)	1	11/17 - ongoing
K506	2014-002274-37	First-in-human clinical study with RNA-Immunotherapy combination of IVAC_W_bre1_*uID* and IVAC_M_u*ID* for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients	triple negative Breast Cancer	3-10	10/16 - ongoing
K638	2017-000817-22	A Phase I, OPen-Label, Multicentre, Non-Randomised Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a POtent and Selective CDK9 Inhibitor	Relapsed and Refractory hematological malignancies	3-5	01/19 - ongoing
K601	2017-004452-37	A first-in-human, randomized, double–blind, placebo-controlled dose escalation trial of a single intravenous dose of the anti-herpes simplex virus monoclonal antibody HDIT101	healthy volunteers Herpes simplex infection	20	05/18 - ongoing